Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Israel-based InSightec has reported that the FDA has approved a label change for the company's ExAblate 2000 MR-guided Focused Ultrasound system for the treatment of women with non-hysteroscopically resectable uterine fibroids.
Subscribe to our email newsletter
Under the new labeling, the agency allows physicians to treat up to 100% of the fibroid compared to its previous restriction to only treat up to half the fibroid tissue.
According to InSightec, the FDA label change was based on a growing body of evidence supporting the system’s safety and efficacy, including the results of a study demonstrating that patients experience longer and improved symptom reduction as a greater volume of the fibroid is destroyed.
Kobi Vortman, president and CEO of InSightec, said: “We’re extremely pleased that the FDA approved this important label change and believe this underscores the safety of our system, the only non-invasive treatment for uterine fibroids available today. We remain committed to continuously expanding our treatment indications and applications through research.”